Priced Oct 22, 2026 · range was $16–$18 · latest SEC filing Nov 4, 2026.
Pinch-zoom for details.
Clinical-stage biotech developing drugs that degrade disease-causing proteins outside cells (its LYTAC platform), starting with autoimmune, inflammatory and allergic diseases.
The filing's own risk-factor headings, shortened.
The filing doesn't set out its strategy in a list we could read.
Source: Lycia Therapeutics, Inc.'s Form 424B4, filed with the SEC on Oct 23, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back